These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 9740352)

  • 1. Cytokines and the mechanisms of action of vaccine adjuvants.
    Brewer JM; Alexander J
    Cytokines Cell Mol Ther; 1997 Dec; 3(4):233-46. PubMed ID: 9740352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccine adjuvant technology: from theoretical mechanisms to practical approaches.
    Schijns VE; Tangerås A
    Dev Biol (Basel); 2005; 121():127-34. PubMed ID: 15962475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New developments in vaccine research--unveiling the secret of vaccine adjuvants.
    de Veer M; Meeusen E
    Discov Med; 2011 Sep; 12(64):195-204. PubMed ID: 21955847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Smart adjuvants.
    Schmidt CS; Morrow WJ; Sheikh NA
    Expert Rev Vaccines; 2007 Jun; 6(3):391-400. PubMed ID: 17542754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Translating innate immunity into immunological memory: implications for vaccine development.
    Pulendran B; Ahmed R
    Cell; 2006 Feb; 124(4):849-63. PubMed ID: 16497593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving vaccine performance with adjuvants.
    Vogel FR
    Clin Infect Dis; 2000 Jun; 30 Suppl 3():S266-70. PubMed ID: 10875797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunology of vaccine adjuvants.
    Ribeiro CM; Schijns VE
    Methods Mol Biol; 2010; 626():1-14. PubMed ID: 20099117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strategies for designing and optimizing new generation vaccines.
    Berzofsky JA; Ahlers JD; Belyakov IM
    Nat Rev Immunol; 2001 Dec; 1(3):209-19. PubMed ID: 11905830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The relevance of cytokines for development of protective immunity and rational design of vaccines.
    Chabalgoity JA; Baz A; Rial A; Grille S
    Cytokine Growth Factor Rev; 2007; 18(1-2):195-207. PubMed ID: 17347024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Designer adjuvants for enhancing the efficacy of infectious disease and cancer vaccines based on suppression of regulatory T cell induction.
    Mills KH
    Immunol Lett; 2009 Feb; 122(2):108-11. PubMed ID: 19100777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current Opinion in Immunology. Vaccines. Introduction.
    Ertl HC; Lanzavecchia A
    Curr Opin Immunol; 2010 Jun; 22(3):355-7. PubMed ID: 20510596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Innate immunity and new adjuvants.
    Mutwiri G; Gerdts V; Lopez M; Babiuk LA
    Rev Sci Tech; 2007 Apr; 26(1):147-56. PubMed ID: 17633299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvants: no longer a 'dirty little secret', but essential key players in vaccines of the future.
    Arakawa T
    Expert Rev Vaccines; 2011 Jan; 10(1):1-5. PubMed ID: 21162613
    [No Abstract]   [Full Text] [Related]  

  • 14. New horizons in adjuvants for vaccine development.
    Reed SG; Bertholet S; Coler RN; Friede M
    Trends Immunol; 2009 Jan; 30(1):23-32. PubMed ID: 19059004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction and direction of immune responses by vaccine adjuvants.
    Schijns VE
    Crit Rev Immunol; 2001; 21(1-3):75-85. PubMed ID: 11642615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How do adjuvants work? Important considerations for new generation adjuvants.
    McKee AS; Munks MW; Marrack P
    Immunity; 2007 Nov; 27(5):687-90. PubMed ID: 18031690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA vaccines--challenges in delivery.
    Pachuk CJ; McCallus DE; Weiner DB; Satishchandran C
    Curr Opin Mol Ther; 2000 Apr; 2(2):188-98. PubMed ID: 11249641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The perfect mix: recent progress in adjuvant research.
    Guy B
    Nat Rev Microbiol; 2007 Jul; 5(7):505-17. PubMed ID: 17558426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Status and future prospects of lipid-based particulate delivery systems as vaccine adjuvants and their combination with immunostimulators.
    Nordly P; Madsen HB; Nielsen HM; Foged C
    Expert Opin Drug Deliv; 2009 Jul; 6(7):657-72. PubMed ID: 19538037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resiquimod and other immune response modifiers as vaccine adjuvants.
    Tomai MA; Miller RL; Lipson KE; Kieper WC; Zarraga IE; Vasilakos JP
    Expert Rev Vaccines; 2007 Oct; 6(5):835-47. PubMed ID: 17931162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.